I le taimi nei, o loʻo iai pea le COVID-19 i tulaga faʻamaʻi i le lalolagi atoa. O le faʻatonuga o Delta ma Omicron variants ua faʻateleina, e mafua ai le faʻaauau pea o le faʻaleleia o latou gafatia faʻasalalau. I le lotolotoi o galu faifai pea o le COVID-19, faʻaopoopo i le COVID-19 tui, o le atinaʻeina o vailaʻau faʻamaʻi COVID-19 ma le vave, faigofie ma le fou o suʻega, ua avea foi ma se manaʻoga fou mo le puipuia ma le puleaina o faʻamaʻi. Viva Biotech Holdings XLement, teu fa'afaigaluegaina ma fa'atumauina e Viva BioInnovator, o lo'o fa'amaoni i le gaosiga o vaila'au fa'afofoga COVID-19 ma su'ega fa'ama'i, e fesoasoani i le tau faasaga i le fa'ama'i COVID-19.
Ian 2022, na faasilasila mai ai e le Medicines Patent Pool (MPP) ua uma ona sainia ni maliega ma le tele o kamupani gaosi oloa e aofia ai le Zhejiang Langhua Pharmaceutical Co., Ltd., o le lala o Viva biotech holdings mo le gaosiga o le gutu COVID-19 antiviral vailaau molnupiravir ma tu'uina atu i totonu ole 105 atunu'u maualalo-ma-ogatotonu-tupe maua (LMICs) e fa'afaigofie ai avanoa taugofie mo le molnupiravir i le lalolagi ma lagolagoina le puipuia ma le puleaina o fa'ama'i fa'apitonu'u. E lima kamupani o le a taulaʻi i le gaosiga o mea mataʻutia, 13 kamupani o le a gaosia uma mea faʻapitoa ma vailaʻau faʻamaeʻa ma kamupani e 9 o le a gaosia le vailaʻau maeʻa.
Ole Vailaau Pateni Fa'afofoga (MPP) ose fa'alapotopotoga fa'alesoifua maloloina lautele o lo'o lagolagoina e Malo Aufaatasi o lo'o galulue e fa'ateleina le avanoa i, ma fa'afaigofie le atina'eina o vaila'au fa'asao ola mo atunu'u maualalo ma feololo tupe maua. O le MPP ma le MSD, le igoa tau fefa'ataua'iga a Merck & Co., Inc Kenilworth NJ USA na sainia se maliega tau laisene ia Oke 2021. I lalo o aiaiga o le maliliega, MPP, e ala i le laisene na tu'uina atu e MSD, o le a fa'atagaina e fa'aopoopo laisene e le fa'apitoa. sublicences i tagata gaosi oloa ma faʻavasega le fale gaosi oloa mo le tuʻuina atu o le molnupiravir faʻamautinoa lelei i atunuʻu o loʻo aofia i le Laisene MPP, i lalo o le faʻatagaga faʻalotoifale.
Molnupiravir (MK-4482 ma EIDD-2801) o se su'esu'ega, tu'u gutu fa'ata'ita'iga o le malosi ribonucleoside analog e taofia ai le toe faia o le SARS-CoV-2 (le mafua'aga o le COVID-19). Molnupiravir o loʻo atiaʻe e le MSD i faiga faʻapaʻaga ma Ridgeback Biotherapeutics, o le vailaʻau faʻamaʻi tuʻu muamua o loʻo avanoa mo togafitiga COVID-19. Fa'amaumauga mai le Vaega 3 MOVE-OUT na fa'aalia ai o togafitiga vave ma le molnupiravir na matua fa'aitiitia ai le lamatiaga o le falema'i po'o le oti i tulaga maualuga, tagata matutua e le'i faia tui ma le COVID-19.
Fai mai le MPP, o kamupani na ofoina atu le sublicence na faʻaalia ma le manuia lo latou gafatia e faʻamalieina manaʻoga a le MPP e fesoʻotaʻi ma le gafatia o le gaosiga, tausisia o tulafono faatonutonu, ma le mafai ona ausia tulaga faʻavaomalo mo vailaʻau faʻamautinoa lelei. O le faʻatagaina na tuʻuina atu i le Langhua Pharmaceutical e le MPP o loʻo faʻatusalia ai se faʻamaoniga maualuga ma le faʻaalia i lona faʻagasologa o le atinaʻeina ma le faʻalauteleina o APIs, faʻaauau le tuʻuina atu, GMP ma le EHS system.
I le aso 2 o Mati, 2022, na maua ai e Xlement, o le NanoSPR biochip ma meafaigāluega biotech kamupani sa teu fa'afaigaluega muamua ma fa'a'au e Viva BioInnovator, le fa'asilasilaga o le pasia o le iloiloga o fa'atinoga mai le Matagaluega o Saienisi ma Tekonolosi a le Malo o Saina. O lana poloketi "R&D ma Mass Production of NanoSPR COVID-19 Particle Test Kit" o se tasi lea o poloketi autu o le "Public Safety Risk Prevention and Control and Emergency Response Technology and Equipment" lea e tautuaina se vaega taua i le COVID-19- su'esu'ega fa'asaienisi feso'ota'i o lo'o fa'aauau i Saina. Faatasi ai ma lona pasi manuia i le asiasiga, Xlement's COVID-19 Test Kit ua faʻamaonia foi e le European Union CE mo le gaosiga tele i le lumanaʻi ma o le a faʻaaogaina vave.
O le fa'aogaina i luga o tekinolosi fa'apitoa NanoSPR chip, na fausia ai e Xlement le pusa fa'ata'ita'i mo vaega o le COVID-19, lea e fa'ataga ai le su'ega e tasi o le tele o siama fa'ama'i mo fa'ata'ita'iga e 96 i totonu ole 15 minute, ma o le ma'ale'ale e latalata ile su'ega o se antigen e tasi. O lenei metotia o loʻo faʻaalia ai le lelei tele pe a faʻatusatusa i vailaʻau faʻataʻitaʻiga o vailaʻau faʻamaʻi viral: e mafai ona faʻaaogaina mo le suʻega a le tagata lava ia i le fale, e faʻapuʻupuʻu tele le taimi o suʻega, ma faʻaitiitia ai le tau o suʻega suʻega ma galuega. Faatasi ai ma le tele o le faʻaaogaina o le NanoSPR tekonolosi i le COVID-19 suʻega na atiaʻe e Xlement, matou te faʻamoemoe e vaʻaia le sili atu ona faigofie suʻesuʻega o masalomia faʻataʻitaʻiga ma luga o le nofoaga suʻesuʻe vave i le tele.
OA MEA E AVEA MAI LENEI TUSI:
- On March 2nd, 2022, Xlement, a devoted NanoSPR biochip and instruments biotech company that previously invested and incubated by Viva BioInnovator, received the notice of passing the performance evaluation from the Ministry of Science and Technology of the People´s Republic of China.
- Under the terms of the agreement, MPP, through the license granted by MSD, will be permitted to further license non-exclusive sublicences to manufacturers and diversify the manufacturing base for the supply of quality-assured molnupiravir to countries covered by the MPP Licence, subject to local regulatory authorization.
- Amid the repeated waves of COVID-19, in addition to COVID-19 vaccine, the development of effective oral COVID-19 drugs and rapid, simple and innovative testing methods have also become a new demand for current epidemic prevention and control.
